Outlook Therapeutics^® Receives European Commission Marketing Authorization for LYTENAVA^™ for the Treatment of Wet AMD

Outlook Therapeutics, Inc. announced that the European Commission has granted Marketing Authorization for LYTENAVA™, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD) in the EU.